RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 7 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. ECOG score ≤ 2, and Child-Pugh classification of A or B;

    Inclusion criterion 3

  3. Patients with prior embolization or other local treatments within 28 days before enrollment, or needing combined local treatment with TACE;

    Exclusion criterion 1

    Received other antitumor systemic treatment within 28 days before enrollment;

    Exclusion criterion 2

    Received blood products or certain corrective treatments within 7 days before enrollment;

    Exclusion criterion 8

  4. Presence of at least one untreated, measurable tumor lesion with a diameter ≥ 3.0 cm according to mRECIST criteria (the maximum diameter of the target lesion ≤ 10.0 cm);

    Inclusion criterion 4

  5. Pregnant, lactating, or planning pregnancy;

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06779461, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age range: 18 to 80 years inclusive, regardless of gender;
  • Patients with primary hepatocellular carcinoma (HCC) at CNLC stage Ib to IIIa who require transarterial chemoembolization (TACE) treatment and are unsuitable for or refuse surgical resection, liver transplantation, and ablation therapy;
  • ECOG score ≤ 2, and Child-Pugh classification of A or B;
  • Presence of at least one untreated, measurable tumor lesion with a diameter ≥ 3.0 cm according to mRECIST criteria (the maximum diameter of the target lesion ≤ 10.0 cm);
  • Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who are willing to receive antiviral treatment throughout the study period;
  • Voluntary participation in this clinical trial and signing of the informed consent form by the subject.

Exclusion Criteria:

  • Patients with prior embolization or other local treatments within 28 days before enrollment, or needing combined local treatment with TACE;
  • Received other antitumor systemic treatment within 28 days before enrollment;
  • Unsuitable for TACE due to lesion characteristics or vascular issues;
  • Vp3/Vp4 portal vein tumor thrombus;
  • Tumor occupying ≥70% of liver volume;
  • Decompensated cirrhosis or recent ascites drainage/TIPS;
  • Severe allergies to contrast agents or embolization materials;
  • Received blood products or certain corrective treatments within 7 days before enrollment;
  • Abnormal blood counts (WBC, platelets, neutrophils, hemoglobin);
  • Abnormal liver function tests (bilirubin, enzymes, albumin);
  • Renal impairment (creatinine, creatinine clearance);
  • Prolonged PT;
  • Unsuitable feeding artery for TACE or embolization risks;
  • Expected survival <6 months;
  • Pregnant, lactating, or planning pregnancy;
  • Factors affecting study results or necessitating study termination (alcoholism, drug abuse, severe diseases);
  • Severe infections unsuitable for TACE;
  • Participation in other clinical trials within 28 days before enrollment;
  • Other reasons deemed unsuitable by the investigator.

Quoted from ClinicalTrials.gov, NCT06779461, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06779461, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06779461